About Design Therapeutics
Design Therapeutics is a company based in Carlsbad (United States) founded in 2006 by Aseem Ansari. Design Therapeutics has raised $170.5 million across 5 funding rounds from investors including BlackRock, Citadel and Janus Henderson Investors. The company has 54 employees as of December 31, 2024. Design Therapeutics offers products and services including GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program. Design Therapeutics operates in a competitive market with competitors including BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Carlsbad, United States
- Employees 54 as on 31 Dec, 2024
- Founders Aseem Ansari
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Design Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$49.59 M (USD)25.84as on Dec 31, 2024
-
EBITDA
-$61.79 M (USD)20.43as on Dec 31, 2024
-
Total Equity Funding
$170.5 M (USD)
in 5 rounds
-
Latest Funding Round
$125 M (USD), Series B
Jan 27, 2021
-
Investors
BlackRock
& 9 more
-
Employee Count
54
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Design Therapeutics
Design Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DSGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Design Therapeutics
Design Therapeutics offers a comprehensive portfolio of products and services, including GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program.
Platform for developing small molecule therapies targeting genetic disorders.
Program advancing treatments for Friedreich ataxia genetic disease.
Program for therapies targeting Fuchs endothelial corneal dystrophy.
Program developing treatments for myotonic dystrophy disorder.
Program focused on therapies for Huntington’s disease patients.
People of Design Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Design Therapeutics
Design Therapeutics has successfully raised a total of $170.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $125 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Design Therapeutics
Design Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked | |
|
A biotechnology venture capital firm investing in innovative science.
|
Locked | Locked | Locked | |
|
Investments are directed toward early and growth stage companies.
|
Locked | Locked | Locked |
Investor details for Design Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Design Therapeutics
Investment portfolio details for Design Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Design Therapeutics
Detailed financials for Design Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Design Therapeutics Comparisons
Peer comparison for Design Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Design Therapeutics
Design Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for rare and orphan diseases
|
|
| Locked | Locked | Locked |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases
|
Detailed competitors of Design Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Design Therapeutics
Complete news archive for Design Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Design Therapeutics
Design Therapeutics was founded in 2006 and raised its 1st funding round 13 years after it was founded.
Design Therapeutics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Design Therapeutics is a funded company, having raised a total of $170.5M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Design Therapeutics is 54.
Design Therapeutics was founded in 2006 and is based in Carlsbad, United States. Focus is placed on biotechnology within the pharmaceutical sector, where disease-modifying therapies for degenerative disorders are developed. Operations involve research and clinical development of targeted treatments. The companys domain, designtx.com, supports these activities. Co-founder Aseem Ansari contributes to strategic direction in this field.
Design Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Design Therapeutics offers GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program.
Yes, Design Therapeutics is publicly traded on NASDAQ under the ticker symbol DSGN.
Design Therapeutics has 10 investors. Key investors include BlackRock, Citadel, Janus Henderson Investors, RA Capital, and Logos Capital.
The ticker symbol of Design Therapeutics is DSGN on NASDAQ.